Ketojenik Diyet Öncesi Metabolik Değerlendirme

Authors

Melis Köse

Synopsis

In the text prepared by Assoc. Prof. Dr. Melis Demir, the metabolic evaluation processes required before initiating a ketogenic diet (KD) are examined in detail. Creating a metabolic process close to a fasting state without inducing catabolism in the organism, KD is effective in conditions such as electron transport chain disorders (complex I deficiency), pyruvate dehydrogenase deficiency, and Glucose Transporter 1 Deficiency (GLUT-1D). The primary goal of pre-diet evaluation is to identify inherited metabolic diseases (IMDs) that pose contraindications and comorbid conditions (kidney stones, hypercholesterolemia, poor weight gain, and chronic metabolic acidosis) that could lead to complications. Since patients with fatty acid metabolism disorders may enter metabolic decompensation during KD, KD is strictly contraindicated in fatty acid transport and oxidation defects such as primary carnitine deficiency, CPTI/CPTII, MCAD, LCAD, and SCAD, as well as pyruvate carboxylase deficiency, porphyria, and ketolysis defects. Standard evaluation includes blood gas, liver and kidney function tests, fasting lipid profile, serum carnitine, acylcarnitine, and urine organic acid analyses, with the addition of blood and urine ketone levels also recommended. In secondary carnitine deficiency, one of the most common side effects, replacement is required if free carnitine falls below 10 µmol/L. Due to increases in triglyceride, total, and LDL cholesterol levels observed in 14-59% of cases, lipid levels should be routinely monitored before treatment and at 1, 6, 12, 18, and 24 months.

References

Scholl-Bürgi S, Höller A, Pichler K, et al. Ketogenic diets in patients with inherited metabolic disorders. J Inherit Metab Dis. 2015; 38:765-73. doi: 10.1007/s10545-015-9872-2. Epub 2015 Jun 25. PMID: 26109259.

Kossoff EH, Zupec-Kania BA, Auvin S,et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3:175-192. doi: 10.1002/epi4.12225. PMID: 29881797; PMCID: PMC5983110.

Arslan N, Guzel O, Kose E, et al. Is ketogenic diet treatment hepatotoxic for children with intractable epilepsy? Seizure. 2016;43:32-38. doi: 10.1016/j.seizure.2016.10.024. Epub 2016 Nov 13.

Ünalp A, Gürbüz G, Edizer S, ve ark. Üçüncü Basamak Bir Çocuk Hastanesindeki Ketojenik Diyet Ekibinin Ketojenik Diyet Tedavisi Deneyimleri. İzmir Dr.Behçet Uz Çocuk hastanesi Dergisi 2018; 8: 175-183

Saudubray JM, Berghe GVD, Walter JH. Inborn metabolic diseases. 5th ed., Springer, Heidelberg, 2006, p.202-222

Dressler A, Stöcklin B, Reithofer E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience. Seizure. 2010;19:404-8. doi: 10.1016/j.seizure.2010.06.006. Epub 2010 Jul 2.

Yılmaz Ü, Edizer S, Köse M, et al. The effect of ketogenic diet on serum lipid concentrations in children with medication resistant epilepsy. Seizure. 202110;91:99-107. doi: 10.1016/j.seizure.2021.06.008. Epub ahead of print.

Asadi M, Rahimlou M, Shishehbor F, Mansoori A. The effect of l-carnitine supplementation on lipid profile and glycaemic control in adults with cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled clinical trials. Clin Nutr. 2020;39:110-122. doi: 10.1016/j.clnu.2019.01.020. Epub 2019 Feb 22.

Published

September 30, 2021

License

License